 This study will look at the PK, safety and tolerability of TAK-831 in healthy participants. The study will enroll approximately 96 participants. The study will include 3 parts: Part 1 single-rising dose SRD, Part 2 SRDmultiple-rising dose MRD, and Part 3 MRD. Participants will be randomly assigned by chance, like flipping a coin to receive either active drug TAK-831 or placebo which will remain undisclosed to the patient and study doctor during the study unless there is an urgent medical need: 